Kailera raises $718.8 million in initial public offering

Kailera Therapeutics Inc. (NASDAQ: KLRA) completed its initial public offering, selling 44,921,875 shares of common stock at $16.00 per share. The biotechnology company raised $718.8 million in gross proceeds before underwriting discounts and other expenses.

The offering included the full exercise of underwriters' option to purchase 5,859,375 additional shares. All shares were offered by the company, with no selling shareholders involved in the transaction.

Kailera's stock began trading on the Nasdaq Global Select Market under the ticker symbol KLRA. The company focuses on obesity care treatments and is in advanced clinical stages of development.

J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI served as joint book-running managers for the offering. William Blair acted as lead manager.

The Securities and Exchange Commission declared the company's registration statement on Form S-1 effective on April 16, 2026. The offering was conducted solely through a prospectus filed with the SEC.

The Waltham, Massachusetts-based company announced the closing of the offering on April 20, 2026, according to the press release.

You May Also Be Interested In

• duPont REGISTRY Group files confidential IPO registration with SEC
• PSQ Holdings announces 1-for-15 reverse stock split effective July 13
• Public Storage prices $900M senior notes offering at 4.855% rate